United States · Industrial & Consumer Products · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Dermata Therapeutics, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
| ROE | -194.2% | -309.68% | 147.65% | 59.58% | 37.33% | 27.25% |
|---|---|---|---|---|---|---|
| Sector average | -213.05% | -30.99% | 76.25% | 96.15% | 83.7% | 17.59% |
| ROA | -132.63% | -184.33% | - | - | - | - |
| Total Assets | $7,863.83K | $341.85K | $341.85K | $341.85K | $341.85K | $341.85K |
| Net Income | -$7,558.56K | -$7,562.58K | -$7,553.76K | -$7,546.22K | -$7,544.02K | -$7,564.85K |